Join the 'Formoterol / glycopyrrolate' group to help and get support from people like you.
Formoterol / glycopyrrolate News
Posted 9 hours ago by Drugs.com
FRIDAY, Dec. 2, 2016 – Research investigating schoolchildren's asthma attacks has pointed to a tiny foe: mice. Allergens from the rodents can infiltrate the air, the study found, and may be a major cause of asthma attacks in the school environment. It's known that many different allergy triggers – from dust mites to mold to pet dander – can fuel children's asthma symptoms. But most research has focused on the triggers in kids' homes. "In this study, we've identified the school as an important factor, too," said researcher Dr. Wanda Phipatanakul, an allergy specialist at Boston Children's Hospital. That said, she stressed, the findings do not actually prove that schools' rodent problems were the cause of kids' symptoms. The next step, Phipatanakul said, is a study where schools will get air purifiers and "integrated pest management," to see if that improves students' respiratory ... Read more
Related support groups: Asthma, Symbicort, Spiriva, Asthma - Maintenance, Fluticasone, Advair Diskus, Advair HFA, Asthma - Acute, Qvar, Combivent, Flovent, Budesonide, Dulera, Entocort, Ipratropium, Mometasone, Bronchial, Atrovent, Breo Ellipta, Entocort EC
Posted 30 Apr 2016 by Drugs.com
25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sean Bohen, Executive Vice-President, Global Medicines Development and Chief Medical Officer, said: “With the approval of Bevespi Aerosphere we are pleased to provide patients with the first LAMA/LABA in a pressurised metered-dose inhaler, delivered using our unique formulation technology. LAMA/LABAs are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active.” Bevespi Aerosphere is a twice-daily, ... Read more